Evidence map›Paper›PMID 31756393›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2020

Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination.

Stephen C Balmert, Cara Donahue Carey, Gabriel D Falo, Shiv K Sethi, Geza Erdos, Emrullah Korkmaz, Louis D Falo

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025
    Review
  12. 3D printed microneedles: revamping transdermal drug delivery systems.Drug delivery and translational research · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Formulating biopharmaceuticals using three-dimensional printing.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Stephen C BalmertDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
Cara Donahue CareyDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
Gabriel D FaloDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
Shiv K SethiDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
Geza ErdosDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States.
Emrullah KorkmazDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States. Electronic address: ek001@pitt.edu.
Louis D FaloDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States; Department of Bioengineering, University of Pittsburgh Swanson School of Engineering, Pittsburgh, PA 15261, United States; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA 15213, United States; UPMC Hillman Cancer Center, Pittsburgh, PA 15232, United States; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15219, United States. Electronic address: lof2@pitt.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
Engineering the Skin Microenvironment to Promote Allergen ToleranceR01AR074285 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FALO, LOUIS D, LITTLE, STEVEN R · 2018 to 2023
$3.0M
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic DermatitisR01AR071277 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FALO, LOUIS D, LARREGINA, ADRIANA T · 2017 to 2021
$2.4M
Manipulating Cutaneous Neuroimmunity to Treat Contact DermatitisR01AR068249 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FALO, LOUIS D, LARREGINA, ADRIANA T · 2015 to 2019
$2.1M
Fabrication and Characterization of Dissolvable Microneedle Arrays for EffectiveR01EB012776 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FALO, LOUIS D · 2010 to 2013
$1.7M
Dendritic Cell Threapy for Cutaneous T-Cell LymphomaR01CA106662 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FALO, LOUIS D · 2005 to 2009
$1.5M
Training Program in Skin Biology and CancerT32CA175294 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2014 to 2018
$973k
NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA121973NCI NIH HHS R01 CA106662NCI NIH HHS T32 CA175294NIAMS NIH HHS R01 AR068249NIAMS NIH HHS R01 AR071277NIAMS NIH HHS R01 AR074285NIBIB NIH HHS R01 EB012776
6 · The paper itself

Abstract

The skin is an attractive tissue target for vaccination, as it is readily accessible and contains a dense population of antigen-presenting and immune-accessory cells. Microneedle arrays (MNAs) are emerging as an effective tool for in situ engineering of the cutaneous microenvironment to enable diverse immunization strategies. Here, we present novel dissolving undercut MNAs and demonstrate their application for effective multicomponent cutaneous vaccination. The MNAs are composed of micron-scale needles featuring pyramidal heads supported by undercut stem regions with filleted bases to ensure successful skin penetration and retention during application. Prior efforts to fabricate dissolving undercut microstructures were limited and required complex and lengthy processing and assembly steps. In the current study, we strategically combine three-dimensional (3D) laser lithography, an emerging micro-additive manufacturing method with unique geometric capabilities and nanoscale resolution, and micromolding with favorable materials. This approach enables reproducible production of dissolving MNAs with undercut microneedles that can be tip-loaded with multiple biocargos, such as antigen (ovalbumin) and adjuvant (Poly(I:C)). The resulting MNAs fulfill the geometric (sharp tips and smooth edges) and mechanical-strength requirements for failure-free penetration of human and murine skin to simultaneously deliver multicomponent (antigen plus adjuvant) vaccines to the same cutaneous microenvironment. Cutaneous vaccination of mice using these MNAs induces more potent antigen-specific cellular and humoral immune responses than those elicited by traditional intramuscular injection. Together, the unique geometric features of these undercut MNAs and the associated manufacturing strategy, which is compatible with diverse drugs and biologics, could enable a broad range of non-cutaneous and cutaneous drug delivery applications, including multicomponent vaccination.

Indexed as

VaccinationVaccinesAdministration, CutaneousAnimalsDrug Delivery SystemsMiceMicroinjectionsNeedlesSkinVaccinesCutaneous immunizationDissolving microneedle arraysMicro-additive manufacturingMulticomponent vaccineTranscutaneous deliveryUndercut microneedles

Identifiers

PMID31756393
PMCPMC8237702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.